IO Biotech Exceeds Q2 2024 EPS Expectations
IO Biotech's Q2 2024 EPS beats estimates, reporting -31 cents vs. expected -35 cents, despite no revenue.
- Latest
- Trending
IO Biotech's Q2 2024 EPS beats estimates, reporting -31 cents vs. expected -35 cents, despite no revenue.
BP's tech could explore Mars or Moon post NASA deal, sharing expertise from hostile environments.
Cognitive technology tested in space on TES-11 to automate satellite communications without human interaction.
Banshee Stealer targets macOS to steal keychain data. Authorities disrupt Dispossessor ransomware, urging global cyber vigilance.
8x8 introduces AI tools to enhance customer experience across its cloud platform for housing associations in the UK.
Recursion Pharmaceuticals merges with Exscientia to revolutionize drug discovery, bringing new treatments to market more quickly.
Fulcrum IT Partners acquires Fortress, boosting cybersecurity offerings with AI integration and strategic expansions.
Toncoin and Dogecoin defy market trends as Rollblock presale promises substantial returns.
Discover Absolute Security's innovative platform tackling cyber threats at Black Hat USA 2024 with remote capabilities for security.
Kyndryl launches Security Operations Center in Bengaluru to combat evolving cyber threats with AI and automation.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.